Header cover image

Norwegian (OSEAX) Biotech Industry Analysis

UpdatedJun 30, 2022
DataAggregated Company Financials
Companies12
  • 7D-2.0%
  • 3M-27.3%
  • 1Y-53.4%
  • YTD-53.7%

Over the last 7 days, the Biotech industry has dropped 2.0%, driven by a pullback from Nykode Therapeutics of 2.0%. The industry has fallen 53% in the last year. Earnings are forecast to grow by 80% annually.

Industry Valuation and Performance

Has the Norwegian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Thu, 30 Jun 2022kr19.5bkr769.9m-kr1,381,086,832.0043.5x
Sat, 28 May 2022kr22.0bkr1.1b-kr1,031,087,618.0039.8x
Mon, 25 Apr 2022kr25.5bkr1.0b-kr986,992,070.0041x
Wed, 23 Mar 2022kr26.2bkr2.7bkr396.9m9.7x
Fri, 18 Feb 2022kr27.9bkr2.7bkr468.8m10.5x
Sun, 16 Jan 2022kr36.5bkr2.2bkr37.2m37.7x
Tue, 14 Dec 2021kr38.5bkr2.2bkr83.3m41.5x
Thu, 11 Nov 2021kr38.3bkr2.6bkr474.7m15.4x
Sat, 09 Oct 2021kr37.5bkr2.6bkr473.4m15x
Mon, 06 Sep 2021kr41.7bkr2.6bkr508.1m18.7x
Wed, 04 Aug 2021kr37.1bkr2.6bkr508.1m15.2x
Sat, 08 May 2021kr41.3bkr2.5bkr545.4m18.5x
Tue, 09 Feb 2021kr35.5bkr2.5bkr675.0m15.8x
Mon, 02 Nov 2020kr26.9bkr235.2m-kr1,189,469,577.0032.6x
Thu, 06 Aug 2020kr22.8bkr252.6m-kr1,172,636,276.3330.2x
Sun, 10 May 2020kr17.5bkr268.6m-kr1,101,468,269.7956.1x
Sat, 01 Feb 2020kr15.8bkr233.9m-kr1,101,022,953.962.5x
Tue, 05 Nov 2019kr7.4bkr189.6m-kr1,043,344,318.00n/a
Fri, 09 Aug 2019kr6.8bkr176.3m-kr1,022,520,318.00n/a
Median PE Ratio

n/a


Total Market Cap: kr6.0bTotal Earnings: -kr1,022,520,318.00Total Revenue: kr176.3mTotal Market Cap vs Earnings and Revenue0%0%0%
Norwegian Biotech Industry Median PE3Y Average 22.6x202020212022
Current Industry PE
  • Investors are pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically.
  • The industry's 3-year average PS ratio 42.7x is higher than the industry's current PS ratio of 25.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 63% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Comparison

How does Norwegian Biotech compare with similar industries?

NO Market2.78%
Healthcare0.50%
Biotech-2.02%
Biotech-2.02%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
EXTX EXACT Therapeuticskr19.002.7%
+kr15.0m
-18.8%PS10982.7x
TRVX Targovaxkr1.034.5%
+kr8.3m
-88.0%PB0.5x
BGBIO BerGenBiokr11.270.8%
+kr8.0m
-53.2%PS1292.4x
ABS Arctic Biosciencekr14.201.4%
+kr4.9m
-34.0%PS16.1x
PCIB PCI Biotech Holdingkr3.930.8%
+kr1.1m
-85.5%PS25x
Simply Wall St™
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

TRVX

kr1.03

Targovax

7D

4.5%

1Y

-88.0%